Literature DB >> 27550072

The Role of Preoperative Magnetic Resonance Imaging in the Assessment and Surgical Treatment of Interval and Screen-Detected Breast Cancer in Older Women.

Martha E Goodrich1, Julie Weiss1, Tracy Onega1,2, Steve L Balch3, Diana S M Buist3, Karla Kerlikowske4,5, Louise M Henderson6, Rebecca A Hubbard3,7.   

Abstract

We describe the relationship between preoperative magnetic resonance imaging (MRI) and the utilization of additional imaging, biopsy, and primary surgical treatment for subgroups of women with interval versus screen-detected breast cancer. We determined the proportion of women receiving additional breast imaging or biopsy and type of primary surgical treatment, stratified by use of preoperative MRI, separately for both groups. Using Breast Cancer Surveillance Consortium (BCSC) data, we identified a cohort of women age 66 and older with an interval or screen-detected breast cancer diagnosis between 2005 and 2010. Using logistic regression, we explored associations between primary surgical treatment type and preoperative MRI use for interval and screen-detected cancers. There were 204 women with an interval cancer and 1,254 with a screen-detected cancer. The interval cancer group was more likely to receive preoperative MRI (21% versus 13%). In both groups, women receiving MRI were more likely to receive additional imaging and/or biopsy. Receipt of MRI was not associated with increased odds of mastectomy (OR = 0.99, 95% CI: 0.67-1.50), while interval cancer diagnosis was associated with significantly higher odds of mastectomy (OR = 1.64, 95% CI: 1.11-2.42). Older women with interval cancer were more likely than women with a screen-detected cancer to have preoperative MRI, however, those with an interval cancer had 64% higher odds of mastectomy regardless of receipt of MRI. Given women with interval cancer are reported to have a worse prognosis, more research is needed to understand effectiveness of imaging modalities and treatment consequences within this group.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; breast surgery; interval breast cancer; preoperative MRI

Mesh:

Year:  2016        PMID: 27550072      PMCID: PMC5118086          DOI: 10.1111/tbj.12651

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  32 in total

1.  Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients.

Authors:  Carrie N Klabunde; Linda C Harlan; Joan L Warren
Journal:  Med Care       Date:  2006-10       Impact factor: 2.983

2.  Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer.

Authors:  Nehmat Houssami; Linn A Abraham; Diana L Miglioretti; Edward A Sickles; Karla Kerlikowske; Diana S M Buist; Berta M Geller; Hyman B Muss; Les Irwig
Journal:  JAMA       Date:  2011-02-23       Impact factor: 56.272

3.  Biologic characteristics of interval and screen-detected breast cancers.

Authors:  F D Gilliland; N Joste; P M Stauber; W C Hunt; R Rosenberg; G Redlich; C R Key
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

4.  Do patients with invasive lobular breast cancer benefit in terms of adequate change in surgical therapy from a supplementary preoperative breast MRI?

Authors:  J Heil; A Buehler; M Golatta; J Rom; A Schipp; A Harcos; A Schneeweiss; G Rauch; C Sohn; H Junkermann
Journal:  Ann Oncol       Date:  2011-04-02       Impact factor: 32.976

5.  Effect of preoperative MRI on mastectomy and contralateral prophylactic mastectomy rates at a community hospital by a single surgeon.

Authors:  Caramarie Guilfoyle; Moira Christoudias; Abigail E Collett; Edward J Gracely; Thomas G Frazier; Andrea V Barrio
Journal:  Breast J       Date:  2014 Jan-Feb       Impact factor: 2.431

6.  Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.

Authors:  Matthew M Poggi; David N Danforth; Linda C Sciuto; Sharon L Smith; Seth M Steinberg; David J Liewehr; Cynthia Menard; Marc E Lippman; Allen S Lichter; Rosemary M Altemus
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  The New Mexico Mammography Project. Screening mammography performance in Albuquerque, New Mexico, 1991 to 1993.

Authors:  R D Rosenberg; J F Lando; W C Hunt; R R Darling; M R Williamson; M N Linver; F D Gilliland; C R Key
Journal:  Cancer       Date:  1996-10-15       Impact factor: 6.860

8.  Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status.

Authors:  Richard J Bleicher; Robin M Ciocca; Brian L Egleston; Linda Sesa; Kathryn Evers; Elin R Sigurdson; Monica Morrow
Journal:  J Am Coll Surg       Date:  2009-06-18       Impact factor: 6.113

9.  MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.

Authors:  Constance D Lehman; Constantine Gatsonis; Christiane K Kuhl; R Edward Hendrick; Etta D Pisano; Lucy Hanna; Sue Peacock; Stanley F Smazal; Daniel D Maki; Thomas B Julian; Elizabeth R DePeri; David A Bluemke; Mitchell D Schnall
Journal:  N Engl J Med       Date:  2007-03-28       Impact factor: 91.245

10.  Patterns of breast magnetic resonance imaging use in community practice.

Authors:  Karen J Wernli; Wendy B DeMartini; Laura Ichikawa; Constance D Lehman; Tracy Onega; Karla Kerlikowske; Louise M Henderson; Berta M Geller; Mike Hofmann; Bonnie C Yankaskas
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

View more
  1 in total

1.  Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer.

Authors:  Karen J Wernli; Laura Ichikawa; Karla Kerlikowske; Diana S M Buist; Susan D Brandzel; Mary Bush; Dianne Johnson; Louise M Henderson; Larissa Nekhlyudov; Tracy Onega; Brian L Sprague; Janie M Lee; Constance D Lehman; Diana L Miglioretti
Journal:  Radiology       Date:  2019-06-04       Impact factor: 29.146

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.